Systemic inflammation in cachexia - Is tumor cytokine expression profile the culprit?

Frontiers in Immunology

Volumn 6, Issue DEC, 2015, Pages

  de Matos Neto, Emidio M ^a   Lima, Joanna D C C ^a   de Pereira, Welbert O ^b   Figuerêdo, Raquel G ^a   Riccardi, Daniela M dos R ^a   Radloff, Katrin ^a   das Neves, Rodrigo X ^a   Camargo, Rodolfo G ^a   Maximiano, Linda F ^a   Tokeshi, Flávio ^a   Otoch, José P ^a   Goldszmid, Romina ^c   Câmara, Niels O S ^a   Trinchieri, Giorgio ^c   de Alcântara, Paulo S M ^a   Seelaender, Marília ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer cachexia; Inflammatory cells; Tumor adipose tissue crosstalk macrophages

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CACHEXIA; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84954206540     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00629     Document Type: Article

References (38)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 12:489-95. doi: 10.1016/S1470-2045(10)70218-7.
2. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol (2015) 22:100-6. doi:10.1016/j.coph.2015.04.003.
3. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol (2013) 10:90-9. doi:10.1038/nrclinonc.2012.209.
4. Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer (1999) 80:444-7. doi:10.1002/(SICI)1097-0215(19990129)80:3<444::AID-IJC18>3.0.CO;2-U.
5. Todorov P, Cariuk P, Mcdevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature (1996) 379:739-42. doi:10.1038/379739a0.
6. Watchorn TM, Waddell I, Dowidar N, Ross JA. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J (2001) 15:562-4. doi:10.1096/fj.00-0534fje.
7. Faber J, Uitdehaag MJ, Spaander M, Van Steenbergen-Langeveld S, Vos P, Berkhout M, et al. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle (2015) 6:32-44. doi:10.1002/jcsm.12009.
8. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition (2000) 16:1015-8. doi:10.1016/S0899-9007(00)00407-X.
9. Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2014:149185. doi:10.1155/2014/149185.
10. Tisdale MJ. Tumor-host interactions. J Cell Biochem (2004) 93:871-7. doi:10.1002/jcb.20246.
11. Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care (2008) 25:407-11. doi:10.1177/1049909108315518.
12. Al-Zoughbi W, Al-Zhoughbi W, Huang J, Paramasivan GS, Till H, Pichler M, et al. Tumor macroenvironment and metabolism. Semin Oncol (2014) 41:281-95. doi:10.1053/j.seminoncol.2014.02.005.
13. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One (2012) 7:e47045. doi:10.1371/journal.pone.0047045.
14. Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine (2005) 32:234-9. doi:10.1016/j.cyto.2005.10.002.
15. Batista ML, Neves RX, Peres SB, Yamashita AS, Shida CS, Farmer SR, et al. Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia. J Endocrinol (2012) 215:363-73. doi:10.1530/JOE-12-0307.
16. Donatto FF, Neves RX, Rosa FO, Camargo RG, Ribeiro H, Matos-Neto EM, et al. Resistance exercise modulates lipid plasma profile and cytokine content in the adipose tissue of tumour-bearing rats. Cytokine (2013) 61:426-32. doi:10.1016/j.cyto.2012.10.021.
17. White JP, Puppa MJ, Narsale A, Carson JA. Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia. Biol Open (2013) 2:1346-53. doi:10.1242/bio.20136544.
18. Argilés JM, Busquets S, Toledo M, López-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care (2009) 3:263-8. doi:10.1097/SPC.0b013e3283311d09.
19. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr (2008) 27:793-9. doi:10.1016/j.clnu.2008.06.013.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods (2001) 25:402-8. doi:10.1006/meth.2001.1262.
21. Yazawa T, Shibata M, Gonda K, Machida T, Suzuki S, Kenjo A, et al. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol (2013) 1:675-9. doi:10.3892/mco.2013.134.
22. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol (2011) 29:415-45. doi:10.1146/annurev-immunol-031210-101322.
23. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol (2012) 30:677-706. doi:10.1146/annurev-immunol-020711-075008.
24. Machado AP, Costa Rosa LF, Seelaender MC. Adipose tissue in walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res (2004) 318:503-14. doi:10.1007/s00441-004-0987-2.
25. Batista ML Jr, Henriques FS, Neves RX, Olivan MR, Matos-Neto EM, Alcântara PSM, et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle (2015). doi:10.1002/jcsm.12037.
26. Neves RX, Rosa-Neto JC, Yamashita AS, Matos-Neto EM, Riccardi DMR, Lira FS, et al. White adipose tissue cells and the progression of cachexia: inflammatory pathways. J Cachexia Sarcopenia Muscle (2015). doi:10.1002/jcsm.12041.
27. Camargo RG, Riccardi DM, Ribeiro HQ, Carnevali LC, De Matos-Neto EM, Enjiu L, et al. NF-κBp65 and expression of its pro-inflammatory target genes are upregulated in the subcutaneous adipose tissue of cachectic cancer patients. Nutrients (2015) 7:4465-79. doi:10.3390/nu7064465.
28. Haugen F, Labori KJ, Noreng HJ, Buanes T, Iversen PO, Drevon CA. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. Arch Physiol Biochem (2011) 117:78-87. doi:10.3109/13813455.2011.560609.
29. Wu CH, Yang MY, Chan KC, Chung PJ, Ou TT, Wang CJ. Improvement in high-fat diet-induced obesity and body fat accumulation by a Nelumbo nucifera leaf flavonoid-rich extract in mice. J Agric Food Chem (2010) 58:7075-81. doi:10.1021/jf101415v.
30. Sullivan-Gunn MJ, Campbell-O'sullivan SP, Tisdale MJ, Lewandowski PA. Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle (2011) 2:181-8. doi:10.1007/s13539-011-0037-3.
31. Mirza KA, Tisdale MJ. Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle. Cell Signal (2012) 24:2118-22. doi:10.1016/j.cellsig.2012.07.016.
32. Mirza KA, Pereira SL, Voss AC, Tisdale MJ. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia. Nutrition (2014) 30:807-13. doi:10.1016/j.nut.2013.11.012.
33. Iijima J, Konno K, Itano N. Inflammatory alterations of the extracellular matrix in the tumor microenvironment. Cancers (2011) 3:3189-205. doi:10.3390/cancers3033189.
34. Trinchieri G. Innate inflammation and cancer: is it time for cancer prevention? F1000 Med Rep (2011) 3:11. doi:10.3410/M3-11.
35. Billingsley KG, Fraker DL, Strassmann G, Loeser C, Fliot HM, Alexander HR. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann Surg Oncol (1996) 3:29-35. doi:10.1007/BF02409048.
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
37. Proctor MJ, Mcmillan DC, Horgan PG, Fletcher CD, Talwar D, Morrison DS. Systemic inflammation predicts all-cause mortality: a glasgow inflammation outcome study. PLoS One (2015) 10:e0116206. doi:10.1371/journal.pone.0116206.
38. Weber M, Moebius P, Büttner-Herold M, Amann K, Preidl R, Neukam FW, et al. Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas-an immunohistochemical study. Br J Cancer (2015) 113:510-9. doi:10.1038/bjc.2015.212.